Long Study - Longitudinal Thrombosis in End Stage Renal Disease

Sponsor
Hamilton Health Sciences Corporation (Other)
Overall Status
Unknown status
CT.gov ID
NCT00157664
Collaborator
Canadian Institutes of Health Research (CIHR) (Other)
400
1
53
7.5

Study Details

Study Description

Brief Summary

The primary focus of this study is to collect information through diagnostic testing, blood sample analysis and patient data collection on patients starting hemodialysis to determine risk and preventative factors of bleeding and clotting events.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Hemodialysis patients have a very high rate of heart attacks, strokes and amputation. These problems are caused by a blood vessel problem called atherosclerosis (hardening of the arteries), and by clotting. Clotting is also a problem in the access, which is their lifeline for hemodialysis. We have early results which show that some risk factors for clotting in the general population are common in dialysis patients. Bleeding is another significant problem within this population. In this pilot study we will measure bleeding/clotting factors in the blood of consenting patients who are just starting dialysis. We will also do special tests to show how much calcium build up and atherosclerotic build up has happened in the arteries and whether the arteries are becoming stiff. We will then follow patients for up to four years and record any health problems that might reflect bleeding, clotting or a blood vessel problem. At the end of the study, we will compare people who have had bleeding, clotting or blood vessel problem with those who have not, and learn which of the measurements predicted problems. We will go on to study potential treatments, such as anti-clotting drugs, which might prevent or delay the occurrence of such problems. This would improve the health of dialysis patients.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Canadian Longitudinal Thrombosis in End Stage Renal Disease Pilot Study
    Study Start Date :
    Jul 1, 2004
    Anticipated Primary Completion Date :
    May 1, 2008
    Anticipated Study Completion Date :
    Dec 1, 2008

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Adult patient (aged > 18 years)

      • Patient on hemodialysis between 30 and 90 days

      Exclusion Criteria:
      • Anticipated recovery of renal function (on dialysis < 90 days)

      • Critical illness at time of recruitment (patients who are critically ill [ICU] when first screened, who survive to 80 days, will be rescreened and will be able to participate at that point if no longer critically ill)

      • Planned live-donor renal transplant within 6 months

      • Patient cannot consent due to language barrier

      • Patient cannot consent due to cognitive difficulties

      • Patient cannot consent due to hearing impairment

      • Patient cannot consent due to speech impairment

      • Patient or decision maker declines consent

      • Patient is unable to give consent and no substitute decision maker is available

      • Patient on dialysis longer than 90 days

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 St. Joseph's Hospital Hamilton Ontario Canada L8N 4A6

      Sponsors and Collaborators

      • Hamilton Health Sciences Corporation
      • Canadian Institutes of Health Research (CIHR)

      Investigators

      • Principal Investigator: Alistair J Ingram, MD, Associate Professor, Medicine
      • Principal Investigator: Catherine M Clase, MD, Associate Professor, Medicine
      • Principal Investigator: Mark A Crowther, MD, Associate Professor, Medicine

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00157664
      Other Study ID Numbers:
      • MOP - 64452
      First Posted:
      Sep 12, 2005
      Last Update Posted:
      Jun 17, 2008
      Last Verified:
      Jun 1, 2008

      Study Results

      No Results Posted as of Jun 17, 2008